The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human clinical trials and more than 190 candidates in preclinical development worldwide as per the WHO on 1 October 2021. The various types of vaccines that are currently approved for emergency use include viral vectors (e.g., adenovirus, University of Oxford/AstraZeneca, Gamaleya Sputnik V, and Johnson & Johnson), mRNA (Moderna and Pfizer-BioNTech), and whole inactivated (Sinovac Biotech and Sinopharm) vaccines. Amidst the emerging cases and shortages of vaccines for global distribution, it is vital to develop a vaccine candidate that recapitulates the severe and fatal progression of COVID-19 and further helps to cope with the current outbreak. Hence, we present the preclinical immunogenicity, protective efficacy, and safety evaluation of a whole-virion inactivated SARS-CoV-2 vaccine candidate (ERUCoV-VAC) formulated in aluminium hydroxide, in three animal models, BALB/c mice, transgenic mice (K18-hACE2), and ferrets. The hCoV-19/Turkey/ERAGEM-001/2020 strain was used for the safety evaluation of ERUCoV-VAC. It was found that ERUCoV-VAC was highly immunogenic and elicited a strong immune response in BALB/c mice. The protective efficacy of the vaccine in K18-hACE2 showed that ERUCoV-VAC induced complete protection of the mice from a lethal SARS-CoV-2 challenge. Similar viral clearance rates with the safety evaluation of the vaccine in upper respiratory tracts were also positively appreciable in the ferret models. ERUCoV-VAC has been authorized by the Turkish Medicines and Medical Devices Agency and has now entered phase 3 clinical development (NCT04942405). The name of ERUCoV-VAC has been changed to TURKOVAC in the phase 3 clinical trial.
【저자키워드】 SARS-CoV-2, Vaccine, COVID-19 vaccine, immunogenicity, Inactivated vaccine, breath, ERUCoV-VAC, TURKOVAC, 【초록키워드】 COVID-19, Viral vector, Efficacy, clinical trial, Vaccines, COVID-19 pandemic, animal models, progression, SARS-CoV-2 vaccine, hACE2, Adenovirus, Spread, Medicine, Viral, outbreak, mice, mRNA, HCoV, viral vectors, vaccine candidate, respiratory, distribution, university, upper respiratory tract, Pfizer-BioNTech, AstraZeneca, Sinovac, inactivated, Moderna, Protective, Emergency use, K18-hACE2, Phase 3, Sinopharm, Device, strain, Medical devices, phase 3 clinical trial, aluminium hydroxide, help, transgenic mice, viral clearance rate, candidate, name, safety evaluation, clinical development, Aluminium, hydroxide, candidate vaccine, human clinical trials, immunogenic, ferrets, BALB/c mice, upper respiratory tracts, Johnson & Johnson, strong immune response, Complete, human clinical trial, was used, develop, include, approved, changed, the WHO, the vaccine, elicited, 【제목키워드】 SARS CoV-2, Inactivated vaccine, development,